The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
Open accessAbstract
BACKGROUND: Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure. METHODS: We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The primary end point was fever with a falciparum parasitemia density of more than 2500 parasites per microliter, and the mean duration of follow-up was 7.9 months (range, 4.5 to 10.5). RESULTS: A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine or the control (rabies) vaccine. Among the 809 children who completed the study procedures according to the protocol, the cumulative number in whom clinical malaria developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as compared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 children were included in the intention-to-treat analysis, which showed an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious adverse events among recipients of RTS,S/AS01E, and this reduction was not only due to a difference in the number of admissions directly attributable to malaria. CONCLUSIONS: RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov number, NCT00380393.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global distribution of clinical episodes of Plasmodium falciparum malaria
Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y., & Hay, S. I. (2005) · Nature · doi:10.1038/nature03342 · Cited by 2,741
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
The global distribution and population at risk of malaria: past, present, and future
Hay, S. I., Guerra, C. A., Tatem, A. J., Noor, A. M., & Snow, R. W. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01043-6 · Cited by 1,001
Baber, N. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb05705.x · Cited by 759
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
Self-citationMalaria: progress, perils, and prospects for eradication
Greenwood, B. M., Fidock, D. A., Kyle, D. E., Kappe, S. H. I., Alonso, P. L., Collins, F. H., & Duffy, P. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33996 · Cited by 709
Artemisinin-Based Combination Treatment of Falciparum Malaria
Nosten, F., & White, N. J. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.181 · Cited by 673
Snow, R. W., Craig, M., Deichmann, U., & Marsh, K. (1999) · PubMed · Cited by 652
Self-citationBhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A.-W., Ramsan, M., Rotllant, G., Gerstenmaier, J. F., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040309 · Cited by 647
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Self-citation
Cited by
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Griffin, J. T., Hollingsworth, T. D., Okell, L. C., Churcher, T. S., White, M., Hinsley, W., Bousema, T., Drakeley, C. J., Ferguson, N. M., Basáñez, M.-G., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000324 · Cited by 595
Self-citationProtection against a Malaria Challenge by Sporozoite Inoculation
Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A. J. F., van Gemert, G. J., van de Vegte-Bolmer, M., van Schaijk, B., Teelen, K., Arens, T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805832 · Cited by 577
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Self-citationRTS,S/AS01 vaccine (Mosquirix™): an overview
Laurens, M. B. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1669415 · Cited by 491
The RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
Neafsey, D. E., Juraska, M., Bedford, T., Benkeser, D., Valim, C., Griggs, A., Lievens, M., Abdulla, S., Adjei, S., Agbenyega, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505819 · Cited by 422
Self-citationSeven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D. C., Njuguna, P., Marsh, K., & Bejon, P. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515257 · Cited by 421
Self-citationDelany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
Crompton, P. D., Kayala, M. A., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G. E., Molina, D. M., Burk, C. R., Waisberg, M., Jasinskas, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001323107 · Cited by 420
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
A Field Trial to Assess a Blood-Stage Malaria Vaccine
Thera, M. A., Doumbo, O. K., Coulibaly, D., Laurens, M. B., Ouattara, A., Kone, A. K., Guindo, A. B., Traore, K., Traore, I., Kouriba, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008115 · Cited by 370
Self-citationHaemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis
Taylor, S. M., Parobek, C. M., & Fairhurst, R. M. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70055-5 · Cited by 347
Climate Change and Cascading Risks from Infectious Disease
Semenza, J. C., Rocklöv, J., & Ebi, K. L. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00647-3 · Cited by 346
Vaccines, new opportunities for a new society
Rappuoli, R., Pizza, M., Del Giudice, G., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402981111 · Cited by 335
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Next‐generation antimalarial drugs: hybrid molecules as a new strategy in drug design
Muregi, F. W., & Ishih, A. (2010) · Drug Development Research · doi:10.1002/ddr.20345 · Cited by 310
Carneiro, I., Roca-Feltrer, A., Griffin, J. T., Smith, L., Tanner, M., Schellenberg, J. A., Greenwood, B., & Schellenberg, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008988 · Cited by 309
Unmet needs in modern vaccinology
Leroux-Roels, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.021 · Cited by 304
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
Kazmin, D., Nakaya, H. I., Lee, E. K., Johnson, M. J., van der Most, R., van den Berg, R. A., Ballou, W. R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621489114 · Cited by 293
Self-citationA 2020 vision for vaccines against HIV, tuberculosis and malaria
Rappuoli, R., & Aderem, A. (2011) · Nature · doi:10.1038/nature10124 · Cited by 273
Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Awuondo, K. O., Leach, A., Lievens, M., Leboulleux, D., Njuguna, P., Peshu, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207564 · Cited by 270
Self-citationAdvances and challenges in malaria vaccine development
Crompton, P. D., Pierce, S. K., & Miller, L. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44423 · Cited by 269
Potential antimalarials from Nigerian plants: A review
Adebayo, J. O., & Krettli, A. U. (2011) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.11.024 · Cited by 267
Hemoglobinopathies: slicing the gordian knot of plasmodium falciparum malaria pathogenesis.
Taylor, S. M., Cerami, C., & Fairhurst, R. M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003327 · Cited by 103
Trends in adjuvant development for vaccines: DAMPs and PAMPs as potential new adjuvants
Miyaji, E. N., Carvalho, E., Oliveira, M. L. S., Raw, I., & Ho, P. L. (2011) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2011007500064 · Cited by 66
“The use of AS02, an oil (squalene)-in-water emulsion of monophosphoryl lipid and the saponin QS21, has led to some level of protection in immunized individuals (53).”
ResultOgieuhi, I. J., Ajekiigbe, V. O., Kolo-Manma, K., Akingbola, A., Odeniyi, T. A., Soyemi, T. S., Ayomide, J. H., Thiyagarajan, B., & Awolola, B. D. (2024) · Discover Public Health · doi:10.1186/s12982-024-00284-w · Cited by 13
Metadata
- Authors
- Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., Demoitié, M.-A., Stallaert, J.-F., Vansadia, P., Carter, T., Njuguna, P., Awuondo, K. O., Malabeja, A., Abdul, O., Gesase, S., Mturi, N., Drakeley, C. J., Savarese, B., Villafana, T., Ballou, W. R., Cohen, J., Riley, E. M., Lemnge, M. M., Marsh, K., & von Seidlein, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-12-11
- Volume
- 359
- Issue
- 24
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124892357
- Cited by
- 417
- References
- 25
- FWCI
- 62.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.